1
Stoffel Markus, Manoharan Muthiah, Rajeev Kallanthottathil G: Chemically modified oligonucleotides for use in modulating micro rna and uses thereof. The Rockefeller University, Alnylam Pharmaceuticals, Stoffel Markus, Manoharan Muthiah, Rajeev Kallanthottathil G, NGUYEN Quang D, July 31, 2008: WO/2008/091703 (18 worldwide citation)

This invention relates generally to chemically modified oligonuceotides useful for modulating expression of microRNAs and pre-microRNAs. More particularly, the invention relates to single stranded chemically modified oligonuceotides for inhibiting microRNA and pre-microRNA expression and to methods ...


2
FEIND DAVID E: Antimicrobial cationic stereoids and methods of use. THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CENTER FOR TECHNOLOGY TRANSFER, Nguyen Quang D, September 9, 2011: WO/2011/109704 (13 worldwide citation)

The invention relates generally to antimicrobial cationic steroid pharmaceutical compositions, methods of making antimicrobial cationic steroid pharmaceutical compositions, and methods of using antimicrobial cationic steroi pharmaceutical compositions.


3
JUNE Carl H, LEVINE Bruce L, PORTER David L, KALOS Michael D: UTILISATION DE LYMPHOCYTES T MODIFIÉS PAR UN RÉCEPTEUR CHIMÉRIQUE DANTIGÈNES CHIMÉRIQUE POUR TRAITER LE CANCER, USE OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS TO TREAT CANCER. THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, JUNE Carl H, LEVINE Bruce L, PORTER David L, KALOS Michael D, NGUYEN Quang D, June 14, 2012: WO/2012/079000 (13 worldwide citation)

The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a ...


4
POWELL Daniel J, COUKOS George, JUNE Carl H: COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DU CANCER, COMPOSITIONS AND METHODS FOR TREATING CANCER. THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, POWELL Daniel J, COUKOS George, JUNE Carl H, NGUYEN Quang D, July 26, 2012: WO/2012/099973 (7 worldwide citation)

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having a-folate receptor (FRα) binding domain and 4- IBB (CD137) costimulatory domain to treat ovarian cancer.


5
KATSIKIS Peter D, KINNEY William A, ALMOND Harold R, KHAN Noshena: [fr] NOUVEAUX INHIBITEURS DE PI3K P110 ET LEURS PROCÉDÉS DUTILISATION, [en] NOVEL PI3K p110 INHIBITORS AND METHODS OF USE THEREOF. PHILADELPHIA HEALTH & EDUCATION CORPORATION, INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH, NGUYEN Quang D, June 20, 2013: WO/2013/090725 (7 worldwide citation)

[en] The invention includes compositions that regulated PI3K p110 delta and are useful as an anti-viral therapy. The invention includes a method of inhibiting p110 delta, a component of PI3K p110 delta signaling pathway, or any combination thereof in a cell as an anti-viral therapeutic approach for ...


6

7
KATSIKIS PETER D: The role of p110 delta signaling in morbidity and lung pathology induced by influenza virus infection. PHILADELPHIA HEALTH AND EDUCATION CORPORATION, Nguyen Quang D, July 22, 2010: WO/2010/083163 (5 worldwide citation)

The invention includes compositions and methods for regulating p110 delta as an anti-influenza virus therapy. The invention includes inhibiting p110 delta, a component of p110 delta signaling pathway, or any combination thereof in a cell as an anti-influenza viral therapeutic approach for treating i ...


8
FRIGAULT Matthew J, ZHAO Yangbing, SCHOLLER John, JUNE Carl H: [fr] TOPICOMPOSITIONS ET PROCÉDÉS POUR PRODUIRE UNE POPULATION DE LYMPHOCYTES T TENACES UTILES DANS LE TRAITEMENT DU CANCER, [en] COMPOSITIONS AND METHODS FOR GENERATING A PERSISTING POPULATION OF T CELLS USEFUL FOR THE TREATMENT OF CANCER. THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NGUYEN Quang D, August 29, 2013: WO/2013/126712 (4 worldwide citation)

[en] The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhi ...


9
JUNE Carl H, SCHOLLER John, POSEY Avery D: [fr] UTILISATION DU DOMAINE DE SIGNALISATION DE CD2 DANS DES RÉCEPTEURS DANTIGÈNE CHIMÈRE DE DEUXIÈME GÉNÉRATION, [en] USE OF THE CD2 SIGNALING DOMAIN IN SECOND-GENERATION CHIMERIC ANTIGEN RECEPTORS. THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NGUYEN Quang D, August 29, 2013: WO/2013/126729 (4 worldwide citation)

[en] The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domai ...


10
JUNE Carl H, KAWALEKAR Omkar U, ZHAO Yangbing, SCHOLLER John: [fr] LYMPHOCYTES T DOUBLES TRANSGÉNIQUES COMPORTANT UN CAR ET UN TCR, ET LEURS PROCÉDÉS DUTILISATION, [en] DOUBLE TRANSGENIC T CELLS COMPRISING A CAR AND A TCR AND THEIR METHODS OF USE. THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NGUYEN Quang D, August 29, 2013: WO/2013/126726 (4 worldwide citation)

[en] The invention provides compositions and methods for reducing and preventing tumor escape from immunotherapy. Specifically, the invention relates to administering a genetically modified T cell comprising both a TCR and a CAR. The invention provides an isolated nucleic acid encoding a T cell rece ...



Click the thumbnails below to visualize the patent trend.